Due to numerous factors, including increased immunogenicity, higher enrichment in tumor-infiltrating lymphocytes (TILs), and a greater quantity of programed cell death ligand 1 (PD-L1) expression, TNBC is more likely than other breast cancer subtypes to benefit from immune checkpoint blockade therapy [21]. This evidence concerns the gene CD274 and neoplasm.